{"transactions":[{"id":4633017,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":60000,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633016,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":262,"price":116.12,"value":30423.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":666568,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633015,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":8230,"price":115.4,"value":949742.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":666830,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633014,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":7601,"price":114.43,"value":869782.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":675060,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633013,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":4876,"price":113.24,"value":552158.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":682661,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633012,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":5506,"price":112.42,"value":618984.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":687537,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633011,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3525,"price":111.44,"value":392826.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":693043,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633010,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.08,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."}],"balance_after":696568,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":713982,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-08T00:00:03.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":false,"shares":4441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":14284,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":4441},"source":{"system":"sec-edgar","filing":"0001193125-26-297817","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526297817/ownership.xml","form_type":"4"}},{"id":713981,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-08T00:00:03.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":false,"shares":45559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":90000,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":45559},"source":{"system":"sec-edgar","filing":"0001193125-26-297817","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526297817/ownership.xml","form_type":"4"}},{"id":713980,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-08T00:00:03.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":119,"value":5950000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."}],"balance_after":666568,"source":{"system":"sec-edgar","filing":"0001193125-26-297817","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526297817/ownership.xml","form_type":"4"}},{"id":713979,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-08T00:00:03.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":2.08,"value":104000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."}],"balance_after":716568,"source":{"system":"sec-edgar","filing":"0001193125-26-297817","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526297817/ownership.xml","form_type":"4"}},{"id":719532,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":135559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719531,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":3336,"price":116.559,"value":388840.824,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.29 to $116.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":666568,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719530,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":44050,"price":115.6883,"value":5096069.615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.31 to $116.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":669904,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719529,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":24105,"price":114.9555,"value":2771002.3275,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.29 to $115.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":713954,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719528,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":6626,"price":113.9758,"value":755203.6508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.36 to $114.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":738059,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719527,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1883,"price":112.8046,"value":212411.0618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.28 to $113.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":744685,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719526,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":80000,"price":2.08,"value":166400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 373 shares acquired under the Registrant's employee stock purchase plan."}],"balance_after":746568,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":798206,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-29T21:00:01.000Z","date":"2026-04-29","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":215559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-192146","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526192146/ownership.xml","form_type":"4"}},{"id":798205,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-29T21:00:01.000Z","date":"2026-04-29","kind":"sale","planned":true,"acquired":false,"shares":936,"price":82.45,"value":77173.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.30 to $83.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":666195,"source":{"system":"sec-edgar","filing":"0001193125-26-192146","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526192146/ownership.xml","form_type":"4"}},{"id":798204,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-29T21:00:01.000Z","date":"2026-04-29","kind":"sale","planned":true,"acquired":false,"shares":12059,"price":81.7,"value":985220.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.23 to $82.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":667131,"source":{"system":"sec-edgar","filing":"0001193125-26-192146","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526192146/ownership.xml","form_type":"4"}},{"id":798203,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-29T21:00:01.000Z","date":"2026-04-29","kind":"sale","planned":true,"acquired":false,"shares":17005,"price":80.74,"value":1372983.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.23 to $81.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":679190,"source":{"system":"sec-edgar","filing":"0001193125-26-192146","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526192146/ownership.xml","form_type":"4"}},{"id":798202,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-29T21:00:01.000Z","date":"2026-04-29","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.08,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":696195,"source":{"system":"sec-edgar","filing":"0001193125-26-192146","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526192146/ownership.xml","form_type":"4"}},{"id":863249,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T23:00:03.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date."}],"balance_after":215000,"derivative":{"exercise_price":90.1,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001193125-26-091980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526091980/ownership.xml","form_type":"4"}},{"id":882640,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-25T22:24:18.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":245559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-072155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526072155/ownership.xml","form_type":"4"}},{"id":882639,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-25T22:24:18.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":8,"price":93.49,"value":747.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":666195,"source":{"system":"sec-edgar","filing":"0001193125-26-072155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526072155/ownership.xml","form_type":"4"}},{"id":882638,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-25T22:24:18.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":1501,"price":92.81,"value":139307.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.20 to $93.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":666203,"source":{"system":"sec-edgar","filing":"0001193125-26-072155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526072155/ownership.xml","form_type":"4"}},{"id":882637,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-25T22:24:18.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":3293,"price":91.76,"value":302165.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.295 to $92.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":667704,"source":{"system":"sec-edgar","filing":"0001193125-26-072155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526072155/ownership.xml","form_type":"4"}},{"id":882636,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-25T22:24:18.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":5434,"price":90.39,"value":491179.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.16 to $90.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":670997,"source":{"system":"sec-edgar","filing":"0001193125-26-072155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526072155/ownership.xml","form_type":"4"}},{"id":882635,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-25T22:24:18.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":19764,"price":89.78,"value":1774411.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.16 to $90.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":676431,"source":{"system":"sec-edgar","filing":"0001193125-26-072155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526072155/ownership.xml","form_type":"4"}},{"id":882634,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-25T22:24:18.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.08,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":696195,"source":{"system":"sec-edgar","filing":"0001193125-26-072155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526072155/ownership.xml","form_type":"4"}},{"id":948455,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T21:40:08.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":false,"shares":3118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date."}],"balance_after":446882,"derivative":{"exercise_price":32.07,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":3118},"source":{"system":"sec-edgar","filing":"0001193125-26-004641","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526004641/ownership.xml","form_type":"4"}},{"id":948454,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:40:08.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":true,"shares":3118,"price":32.07,"value":99994.26,"ownership":{"direct":true},"balance_after":666195,"source":{"system":"sec-edgar","filing":"0001193125-26-004641","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526004641/ownership.xml","form_type":"4"}},{"id":956749,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-31T22:23:32.000Z","date":"2025-12-31","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":275559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-25-338415","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525338415/ownership.xml","form_type":"4"}},{"id":956748,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-31T22:23:32.000Z","date":"2025-12-31","kind":"sale","planned":true,"acquired":false,"shares":6014,"price":78.5187,"value":472211.4618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.44 to $78.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":663077,"source":{"system":"sec-edgar","filing":"0001193125-25-338415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525338415/ownership.xml","form_type":"4"}},{"id":956747,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-31T22:23:32.000Z","date":"2025-12-31","kind":"sale","planned":true,"acquired":false,"shares":23986,"price":77.9508,"value":1869727.8888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.44 to $78.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":669091,"source":{"system":"sec-edgar","filing":"0001193125-25-338415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525338415/ownership.xml","form_type":"4"}},{"id":956746,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-31T22:23:32.000Z","date":"2025-12-31","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.08,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":693077,"source":{"system":"sec-edgar","filing":"0001193125-25-338415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525338415/ownership.xml","form_type":"4"}},{"id":965949,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T23:07:57.000Z","date":"2025-12-17","kind":"exercise","planned":false,"acquired":false,"shares":2595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":272505,"derivative":{"exercise_price":38.53,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":2595},"source":{"system":"sec-edgar","filing":"0001193125-25-323092","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525323092/ownership.xml","form_type":"4"}},{"id":965948,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-17T23:07:57.000Z","date":"2025-12-17","kind":"exercise","planned":false,"acquired":true,"shares":2595,"price":38.53,"value":99985.35,"ownership":{"direct":true},"balance_after":663077,"source":{"system":"sec-edgar","filing":"0001193125-25-323092","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525323092/ownership.xml","form_type":"4"}},{"id":978196,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-08T23:09:20.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":305559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-25-311504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525311504/ownership.xml","form_type":"4"}},{"id":978195,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-08T23:09:20.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":100000,"price":89.17,"value":8917000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":660482,"source":{"system":"sec-edgar","filing":"0001193125-25-311504","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525311504/ownership.xml","form_type":"4"}},{"id":978194,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-08T23:09:20.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":100000,"price":2.08,"value":208000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":760482,"source":{"system":"sec-edgar","filing":"0001193125-25-311504","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525311504/ownership.xml","form_type":"4"}},{"id":1012233,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-29T21:19:12.000Z","date":"2025-10-29","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":405559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-25-256673","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525256673/ownership.xml","form_type":"4"}},{"id":1012232,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-29T21:19:12.000Z","date":"2025-10-29","kind":"sale","planned":true,"acquired":false,"shares":3627,"price":61.4576,"value":222906.7152,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.37 to $61.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":660482,"source":{"system":"sec-edgar","filing":"0001193125-25-256673","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525256673/ownership.xml","form_type":"4"}},{"id":1012231,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-29T21:19:12.000Z","date":"2025-10-29","kind":"sale","planned":true,"acquired":false,"shares":24511,"price":61.0186,"value":1495626.9046,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.37 to $61.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":664109,"source":{"system":"sec-edgar","filing":"0001193125-25-256673","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525256673/ownership.xml","form_type":"4"}},{"id":1012230,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-29T21:19:12.000Z","date":"2025-10-29","kind":"sale","planned":true,"acquired":false,"shares":1862,"price":59.7225,"value":111203.295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.35 to $60.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":688620,"source":{"system":"sec-edgar","filing":"0001193125-25-256673","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525256673/ownership.xml","form_type":"4"}},{"id":1012229,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-29T21:19:12.000Z","date":"2025-10-29","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.08,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":690482,"source":{"system":"sec-edgar","filing":"0001193125-25-256673","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525256673/ownership.xml","form_type":"4"}},{"id":1039801,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-16T20:11:45.000Z","date":"2025-09-16","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":435559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-25-204997","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525204997/ownership.xml","form_type":"4"}},{"id":1039800,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-16T20:11:45.000Z","date":"2025-09-16","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":49,"value":1470000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":660482,"source":{"system":"sec-edgar","filing":"0001193125-25-204997","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525204997/ownership.xml","form_type":"4"}},{"id":1039799,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-16T20:11:45.000Z","date":"2025-09-16","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.08,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":690482,"source":{"system":"sec-edgar","filing":"0001193125-25-204997","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312525204997/ownership.xml","form_type":"4"}},{"id":1126254,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-03T22:30:05.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":465559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-081199","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017025081199/ownership.xml","form_type":"4"}},{"id":1126253,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-03T22:30:05.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":49,"value":1470000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."}],"balance_after":660482,"source":{"system":"sec-edgar","filing":"0000950170-25-081199","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017025081199/ownership.xml","form_type":"4"}},{"id":1126252,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-03T22:30:05.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.08,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025."}],"balance_after":690482,"source":{"system":"sec-edgar","filing":"0000950170-25-081199","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017025081199/ownership.xml","form_type":"4"}},{"id":1237034,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T23:30:03.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":365000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date."}],"balance_after":365000,"derivative":{"exercise_price":30.17,"expiration_date":"2035-03-02","underlying":"Common Stock","underlying_shares":365000},"source":{"system":"sec-edgar","filing":"0000950170-25-031145","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017025031145/ownership.xml","form_type":"4"}},{"id":1304544,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-13T12:00:04.000Z","date":"2025-01-10","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vested in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":495559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-25-004549","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017025004549/ownership.xml","form_type":"4"}},{"id":1304543,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-13T12:00:04.000Z","date":"2025-01-10","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":659959,"source":{"system":"sec-edgar","filing":"0000950170-25-004549","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017025004549/ownership.xml","form_type":"4"}},{"id":1466529,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:30:10.000Z","date":"2024-07-01","kind":"exercise","planned":false,"acquired":false,"shares":18773,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of May 14, 2020, subject to the reporting person's continued employment through each vesting date."}],"balance_after":288456,"derivative":{"exercise_price":5.33,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":18773},"source":{"system":"sec-edgar","filing":"0000950170-24-079666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017024079666/ownership.xml","form_type":"4"}},{"id":1466528,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-01T20:30:10.000Z","date":"2024-07-01","kind":"exercise","planned":false,"acquired":true,"shares":18773,"price":5.33,"value":100060.09,"ownership":{"direct":true},"balance_after":649959,"source":{"system":"sec-edgar","filing":"0000950170-24-079666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017024079666/ownership.xml","form_type":"4"}},{"id":1473885,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T12:30:03.000Z","date":"2024-06-18","kind":"exercise","planned":false,"acquired":false,"shares":14413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":505559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":14413},"source":{"system":"sec-edgar","filing":"0000950170-24-075332","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017024075332/ownership.xml","form_type":"4"}},{"id":1473884,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-20T12:30:03.000Z","date":"2024-06-18","kind":"exercise","planned":false,"acquired":true,"shares":14413,"price":2.08,"value":29979.04,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This number includes 1,203 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024."}],"balance_after":631186,"source":{"system":"sec-edgar","filing":"0000950170-24-075332","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017024075332/ownership.xml","form_type":"4"}},{"id":1604558,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T23:12:59.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":530000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date."}],"balance_after":530000,"derivative":{"exercise_price":43.5,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":530000},"source":{"system":"sec-edgar","filing":"0000950170-24-025085","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017024025085/ownership.xml","form_type":"4"}},{"id":1697042,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-02T22:43:37.000Z","date":"2024-01-02","kind":"exercise","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":519972,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-24-000386","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017024000386/ownership.xml","form_type":"4"}},{"id":1697041,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-02T22:43:37.000Z","date":"2024-01-02","kind":"exercise","planned":false,"acquired":true,"shares":9000,"price":2.08,"value":18720.0,"ownership":{"direct":true},"balance_after":615570,"source":{"system":"sec-edgar","filing":"0000950170-24-000386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017024000386/ownership.xml","form_type":"4"}},{"id":1749035,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-06T23:00:05.000Z","date":"2023-11-03","kind":"exercise","planned":false,"acquired":false,"shares":17632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":528972,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":17632},"source":{"system":"sec-edgar","filing":"0000950170-23-059580","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017023059580/ownership.xml","form_type":"4"}},{"id":1749034,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-06T23:00:05.000Z","date":"2023-11-03","kind":"exercise","planned":false,"acquired":false,"shares":2368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.08,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":2368},"source":{"system":"sec-edgar","filing":"0000950170-23-059580","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017023059580/ownership.xml","form_type":"4"}},{"id":1749033,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-06T23:00:05.000Z","date":"2023-11-03","kind":"exercise","planned":false,"acquired":true,"shares":17632,"price":2.08,"value":36674.56,"ownership":{"direct":true},"balance_after":606570,"source":{"system":"sec-edgar","filing":"0000950170-23-059580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017023059580/ownership.xml","form_type":"4"}},{"id":1749032,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-06T23:00:05.000Z","date":"2023-11-03","kind":"exercise","planned":false,"acquired":true,"shares":2368,"price":2.08,"value":4925.44,"ownership":{"direct":true},"balance_after":588938,"source":{"system":"sec-edgar","filing":"0000950170-23-059580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017023059580/ownership.xml","form_type":"4"}},{"id":1813279,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-08T20:30:52.000Z","date":"2023-08-08","kind":"exercise","planned":false,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option vested in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":2368,"derivative":{"exercise_price":2.08,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000950170-23-039894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017023039894/ownership.xml","form_type":"4"}},{"id":1813278,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-08T20:30:52.000Z","date":"2023-08-08","kind":"exercise","planned":false,"acquired":true,"shares":12000,"price":2.08,"value":24960.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This number includes 870 shares acquired under the Registrant's employee stock purchase plan on May 31, 2023."}],"balance_after":586570,"source":{"system":"sec-edgar","filing":"0000950170-23-039894","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000095017023039894/ownership.xml","form_type":"4"}},{"id":1976111,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T21:31:27.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date."}],"balance_after":450000,"derivative":{"exercise_price":32.07,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-23-006986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924323006986/doc4.xml","form_type":"4"}},{"id":2092612,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-08T23:11:29.000Z","date":"2022-12-08","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones."}],"balance_after":18725,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-038010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322038010/doc4.xml","form_type":"4"}},{"id":2092611,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-08T23:11:29.000Z","date":"2022-12-08","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This number includes 1,769 shares acquired under the Registrant's employee stock purchase plan on December 1, 2022."}],"balance_after":573700,"source":{"system":"sec-edgar","filing":"0000899243-22-038010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322038010/doc4.xml","form_type":"4"}},{"id":2136645,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-18T00:09:26.000Z","date":"2022-10-17","kind":"exercise","acquired":false,"shares":27676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":546604,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":27676},"source":{"system":"sec-edgar","filing":"0000899243-22-033709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322033709/doc4.xml","form_type":"4"}},{"id":2136644,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-18T00:09:26.000Z","date":"2022-10-17","kind":"exercise","acquired":false,"shares":32056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":14368,"derivative":{"exercise_price":2.08,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":32056},"source":{"system":"sec-edgar","filing":"0000899243-22-033709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322033709/doc4.xml","form_type":"4"}},{"id":2136643,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-18T00:09:26.000Z","date":"2022-10-17","kind":"exercise","acquired":true,"shares":27676,"price":2.08,"value":57566.08,"ownership":{"direct":true},"balance_after":561931,"source":{"system":"sec-edgar","filing":"0000899243-22-033709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322033709/doc4.xml","form_type":"4"}},{"id":2136642,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-18T00:09:26.000Z","date":"2022-10-17","kind":"exercise","acquired":true,"shares":32056,"price":2.08,"value":66676.48,"ownership":{"direct":true},"balance_after":534255,"source":{"system":"sec-edgar","filing":"0000899243-22-033709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322033709/doc4.xml","form_type":"4"}},{"id":2285106,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-03T23:27:56.000Z","date":"2022-05-03","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":46424,"derivative":{"exercise_price":2.08,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-016431","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322016431/doc4.xml","form_type":"4"}},{"id":2285105,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-03T23:27:56.000Z","date":"2022-05-03","kind":"exercise","acquired":true,"shares":20000,"price":2.08,"value":41600.0,"ownership":{"direct":true},"balance_after":502199,"source":{"system":"sec-edgar","filing":"0000899243-22-016431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322016431/doc4.xml","form_type":"4"}},{"id":2356793,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:31:14.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":275100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date."}],"balance_after":275100,"derivative":{"exercise_price":38.53,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":275100},"source":{"system":"sec-edgar","filing":"0000899243-22-009081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322009081/doc4.xml","form_type":"4"}},{"id":2435279,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-14T22:30:12.000Z","date":"2022-01-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":66424,"derivative":{"exercise_price":2.08,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-002022","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322002022/doc4.xml","form_type":"4"}},{"id":2435278,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-14T22:30:12.000Z","date":"2022-01-14","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":482199,"source":{"system":"sec-edgar","filing":"0000899243-22-002022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322002022/doc4.xml","form_type":"4"}},{"id":2437143,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-12","kind":"exercise","acquired":false,"shares":8612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":574280,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":8612},"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437142,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":16923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":582892,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":16923},"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437141,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-10","kind":"exercise","acquired":false,"shares":22465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":599815,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":22465},"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437140,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":241,"price":53.97,"value":13006.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."}],"balance_after":472199,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437139,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":1623,"price":53.27,"value":86457.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.88 to $53.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":472440,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437138,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":4022,"price":52.0163,"value":209209.5586,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.60 to $52.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":474063,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437137,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":2726,"price":51.3122,"value":139877.0572,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.60 to $51.575. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":478085,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437136,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-12","kind":"exercise","acquired":true,"shares":8612,"price":2.08,"value":17912.96,"ownership":{"direct":true},"balance_after":480811,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437135,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":347,"price":55.0529,"value":19103.3563,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.05 to $55.06. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":472199,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437134,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":6644,"price":54.4224,"value":361582.4256,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.01 to $54.995. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":472546,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437133,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":9932,"price":53.6759,"value":533109.0388,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.01 to $54.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":479190,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437132,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":16923,"price":2.08,"value":35199.84,"ownership":{"direct":true},"balance_after":489122,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437131,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":106,"price":54.99,"value":5828.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."}],"balance_after":472199,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437130,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":4201,"price":54.4026,"value":228545.3226,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.99 to $54.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":472305,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437129,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":10673,"price":53.3476,"value":569378.9348,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.99 to $53.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":476506,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437128,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":7485,"price":52.4574,"value":392643.639,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.99 to $52.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":487179,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2437127,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-13T00:30:12.000Z","date":"2022-01-10","kind":"exercise","acquired":true,"shares":22465,"price":2.08,"value":46727.2,"ownership":{"direct":true},"balance_after":494664,"source":{"system":"sec-edgar","filing":"0000899243-22-001807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924322001807/doc4.xml","form_type":"4"}},{"id":2470579,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-16T21:49:05.000Z","date":"2021-12-16","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date."}],"balance_after":76424,"derivative":{"exercise_price":2.08,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000899243-21-048614","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000089924321048614/doc4.xml","form_type":"4"}}],"next_cursor":"2021-12-16T21:49:05.000000Z,2470579"}